newsfilter
← Latest News
ClinicalTrials.gov·

Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China - NCT05876351

Number of Participants Considered as Complete Thrombotic Microangiopathy (TMA) Responders, Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Pharmacokinetics (PK): Serum Eculizumab Concentration, (and 8 more...)